Results 71 to 80 of about 12,593 (182)

Human Embryonic Stem Cell‐Derived Immunity‐And‐Matrix‐Regulatory Cells Attenuate Pulmonary Fibrosis via MMP1‐Mediated Collagen Degradation

Cell Proliferation, EarlyView.
Human embryonic stem cell‐derived Immunity‐and‐Matrix‐Regulatory Cells (IMRCs) effectively attenuate pulmonary fibrosis by secreting Matrix Metalloproteinase‐1 (MMP1), which directly degrades excess collagen I in the extracellular matrix. By directly degrading collagen I, IMRCs reverse ECM stiffness, suppress myofibroblast activation, and promote a ...
Zhongwen Li, Dingyun Song, Faguo Sun, Licheng Song, Bin An, Tingting Gao, Jingjing Liu, Kan Zhang, Kaidi Liu, Kaiwei Wu, Yajing Li, Yi Yang, Yaru Liu, Ruofan Su, Zai Wang, Tiemei Zhao, Huaiyong Chen, Li Xiao, Liang Peng, Liu Wang, Wei Li, Lixin Xie, Jie Hao, Huaping Dai, Jun Wu   +24 more
wiley   +1 more source

Pirfenidone treatment of idiopathic pulmonary fibrosis

, 2012
Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3–
Arata Azuma
core   +1 more source

Epigenomic Cascades Across Organs in Metabolic Dysfunction–Associated Steatotic Liver Disease: New Therapeutic Horizons

Obesity Reviews, EarlyView.
ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common chronic liver disorder worldwide, affecting approximately one‐third of the population and increasing the risk of severe hepatic and cardiovascular complications.
Shurui Yang, Zhongyu Huang, Sanchun Tan, Fengxia Liang, Li Chen   +4 more
wiley   +1 more source

Role of transient receptor potential vanilloid 4 in therapeutic anti-fibrotic effects of pirfenidone

, 2022
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal lung disorder characterized by aberrant extracellular matrix deposition in the interstitium. Pirfenidone is an anti-fibrotic agent used to treat patients with IPF.
Koji Kuronuma (9638138)
core   +1 more source

Cancer‐associated fibroblast heterogeneity across solid and haematological malignancies: Lessons from colorectal cancer and multiple myeloma

The Journal of Physiology, EarlyView.
Abstract figure legend CAF origins and plasticity give rise to distinct phenotypes with immunosuppressive functions in colorectal cancer and multiple myeloma. These distinct CAF phenotypes contribute to immunosuppressive tumour microenvironments through ECM remodelling, cytokine signalling and immune regulation.
Hui Mo, Haoyan Han, Michael O'Dwyer, Eileen Reidy, Aideen E. Ryan   +4 more
wiley   +1 more source

Supplemental data_Role of transient receptor potential vanilloid 4 in therapeutic anti-fibrotic effects of pirfenidone

, 2022
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal lung disorder characterized by aberrant extracellular matrix deposition in the interstitium.
Koji Kuronuma (9638138)
core   +1 more source

Therapeutic use of pirfenidone against septic shock

, 1997
Tumor necrosis factor (TNF) is an extremely potent cytokine which is involved in the pathogenesis of a number of diseases. Interruption of its synthesis can result in a reduction of inflammation and subsequent pathology.
Cain, William C
core   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Pirfenidone: A novel hypothetical treatment for COVID-19

, 2020
Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome (ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A fulminant ARDS kills the majority of COVID-19 victims. Pirfenidone (5-methyl-1-
Seifirad, Soroush
core   +1 more source

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

Respiratory Research, 2011
Background A phase III trial in Japan showed that pirfenidone is effective for idiopathic pulmonary fibrosis (IPF). To find out which patients specifically benefit from pirfenidone, we analyzed in an exploratory manner the data from the phase III trial ...
Takahashi Hiroki, Suga Moritaka, Kondoh Yasuhiro, Taniguchi Hiroyuki, Ebina Masahito, Ogura Takashi, Taguchi Yoshio, Azuma Arata, Nakata Koichiro, Sato Atsuhiko, Kudoh Shoji, Nukiwa Toshihiro   +11 more
doaj   +1 more source